These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8337414)

  • 1. Effects of ridogrel on the prostacyclin-thromboxane ratio in nulliparous third trimester-pregnant rhesus monkeys.
    Keith JC; Goodrich JA; Endo Y; Taub D; Mehlman P; Ward G
    Prostaglandins; 1993 Jun; 45(6):547-55. PubMed ID: 8337414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ridogrel improves maternal/fetal homeostasis in an ovine model of pregnancy-induced hypertension.
    Keith JC; Endo Y; Warwick K; Keith KE; Brugh S; Rowles TK
    Prostaglandins; 1994 Mar; 47(3):247-63. PubMed ID: 8016393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placental transfer of the thromboxane synthetase inhibitor ridogrel in the late-pregnant ewe.
    Schneider TJ; Struijk PC; Wallenburg HC
    Eur J Obstet Gynecol Reprod Biol; 1999 Sep; 86(1):83-7. PubMed ID: 10471147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ridogrel, a thromboxane synthase inhibitor and receptor antagonist, on blood pressure in the spontaneously hypertensive rat.
    Quest DW; Wilson TW
    Jpn J Pharmacol; 1998 Dec; 78(4):479-86. PubMed ID: 9920205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thromboxane A2 receptor antagonism and synthase inhibition in essential hypertension.
    Ritter JM; Barrow SE; Doktor HS; Stratton PD; Edwards JS; Henry JA; Gould S
    Hypertension; 1993 Aug; 22(2):197-203. PubMed ID: 8340155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ridogrel in the setting of percutaneous transluminal coronary angioplasty.
    Timmermans C; Vrolix M; Vanhaecke J; Stammen F; Piessens J; Vercammen E; De Geest H
    Am J Cardiol; 1991 Aug; 68(5):463-6. PubMed ID: 1872272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT).
    Circulation; 1994 Feb; 89(2):588-95. PubMed ID: 8313547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung.
    Bureau MF; De Clerck F; Lefort J; Arreto CD; Vargaftig BB
    J Pharmacol Exp Ther; 1992 Feb; 260(2):832-40. PubMed ID: 1738127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase.
    Vandeplassche G; Hermans C; Somers Y; Van de Werf F; de Clerck F
    J Am Coll Cardiol; 1993 Apr; 21(5):1269-79. PubMed ID: 8459087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The in vitro effect of ridogrel on platelet function in normocholesterolaemic and familial hypercholesterolaemic type IIa subjects.
    Naran NH; Chetty N
    Thromb Res; 1997 Dec; 88(5):399-407. PubMed ID: 9556227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK; Ober JC; Ferguson JJ; Anderson HV; Maraganore J; Buja LM; Willerson JT
    Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries.
    Vandeplassche G; Hemans C; Van de Water A; Xhonneux R; Wouters L; Van Ammel K; De Clerck F
    Circ Res; 1991 Aug; 69(2):313-24. PubMed ID: 1830517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man.
    Weber C; Beetens JR; Tegtmeier F; Van Rooy P; Vercammen E; Wouters L; De Clerck F
    Thromb Haemost; 1992 Aug; 68(2):214-20. PubMed ID: 1412169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostacyclin, thromboxane and glomerular filtration rate are abnormal in sickle cell pregnancy.
    Obilade OA; Akanmu AS; Broughton Pipkin F; Afolabi BB
    PLoS One; 2017; 12(9):e0184345. PubMed ID: 28880908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ridogrel: a selective inhibitor of the cytochrome P450-dependent thromboxane synthesis.
    Vanden Bossche H; Willemsens G; Bellens D; Janssen PA
    Biochem Pharmacol; 1992 Feb; 43(4):739-44. PubMed ID: 1540227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of thromboxane and prostaglandins in human blood in the presence of thromboxane synthase inhibitors: a comparison of RIA and GC/MS determinations.
    Weber C; Beetens JR; Van de Wiele R; Höller M; De Clerck F
    Blood Coagul Fibrinolysis; 1991 Feb; 2(1):7-15. PubMed ID: 1773000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ridogrel, a new platelet antiaggregant molecule with a double mechanism of action. A pharmacological and clinical profile].
    Di Perri T; Notari M; Assogna G
    Recenti Prog Med; 1991 Oct; 82(10):533-40. PubMed ID: 1759039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of flunixin meglumine, phenylbutazone and a selective thromboxane synthetase inhibitor (UK-38,485) on thromboxane and prostacyclin production in healthy horses.
    Hardee MM; Moore JN; Hardee GE
    Res Vet Sci; 1986 Mar; 40(2):152-6. PubMed ID: 3517992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis.
    Casellas F; Papo M; Guarner F; Antolín M; Segura RM; Armengol JR; Malagelada JR
    Eur J Gastroenterol Hepatol; 1995 Mar; 7(3):221-6. PubMed ID: 7743303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do prostacyclin and thromboxane play a role in endotoxic shock?
    Webb PJ; Westwick J; Scully MF; Zahavi J; Kakkar VV
    Br J Surg; 1981 Oct; 68(10):720-4. PubMed ID: 7025959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.